Retrophin Inc (RTRX) reported quarterly earnings results on Tuesday, May-3-2016. The company said it had a profit of $0.14 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.41. Analysts had a consensus of $-0.27. The company posted revenue of $29.00 million in the period, compared to analysts expectations of $31.00 million. The company’s revenue was up 66.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.18 EPS.
Retrophin Inc opened for trading at $13.89 and hit $14.26 on the upside on Monday, eventually ending the session at $14.26, with a gain of 3.48% or 0.48 points. The heightened volatility saw the trading volume jump to 5,81,639 shares. Company has a market cap of $521 M.
In a different news, on Mar 7, 2016, Jeffrey A Meckler (director) purchased 5,000 shares at $15.31 per share price. According to the SEC, on Mar 1, 2016, Alvin Shih (EVP of Research & Development) sold 8,750 shares at $14.35 per share price. On Nov 12, 2015, Steve Aselage (Chief Executive Officer) sold 60,000 shares at $18.75 per share price, according to the Form-4 filing with the securities and exchange commission.
Retrophin Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery acquisition development and commercialization of drugs for the treatment of debilitating and life-threatening diseases. The Company is focused on various catastrophic diseases affecting children including focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN). The Company is engaged in enrolling patients in a Phase II clinical trial for its lead compound Sparsentan for FSGS. The Company’s products include Thiola (Tiopronin) and Chenodal. Its Thiola is used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Chenodal is a tablet of chenodiol (chenodeoxycholic acid). Its other products include RE-024 and RE-034 which are in pre-clinical stage.